January 29th 2025
The platform is live with full functionality for use by marketing authorization holders and national competent authorities to report drug supply information.
EMA Says No Evidence for Link between Type 2 Diabetes Drugs and Suicidal Tendencies
April 12th 2024The agency’s risk assessment committee has concluded that available evidence has not been found that supports a causal association between glucagon-like peptide-1 receptor agonists and self-harming thoughts and actions.
Europa Perspectives: EMA Transparency in Investigating CAR-T Secondary Cancers
February 28th 2024Steffen Thirstrup, chief medical officer, EMA, emphasizes the importance of transparency in investigating potential safety issues of CAR-T therapies, while highlighting the need to balance regulatory diligence with maintaining trust within the community and among stakeholders.